Summit Therapeutics (SMMT) Tops Q4 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/19/2026
- Tech selloff weighs down Wall Street as bond yields climb
- Baidu slips as Q2 results miss estimates despite growth in AI cloud business
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Home Depot beats estimates, reaffirms fiscal 2026 guidance
- Citi says positioning risk is shifting from short squeezes to profit-taking
- Tech selloff weighs down Wall Street as bond yields climb
- Francisco Partners to acquire Weave Communications for $650M
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Goldman Sachs to acquire real estate company LCN for up to $410M
- BofA raises hyperscaler AI capex outlook to $3.6tn through 2028
Stifel Reiterates Hold Rating on Summit Therapeutics plc (SMMT)
February 24, 2025 1:40 PM ESTStifel analyst Brad Canino reiterated a Hold rating and $40.00 price target on Summit Therapeutics plc (NASDAQ: SMMT)
The analyst comments "Todays volatility is likely recent M&A conjecture falling out after management canceled three 1Q bank conferences, and less of a... More
